All content for OncoPharm is the property of John Bossaer and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?
The 5-year+ follow-up from CARTITUDE-1 has people asking if cilta-cel can cure multiple myeloma? We discuss this data and the broad comparison to the other BCMA-targeting CAR-T product, idi-cel and a recent comparison on plasma cell leukemia.
CARTITUDE-1 Long-Term F/U: https://doi.org/10.1200/JCO-25-00760
Cilta-cel & ide-cel in plasma cell leukemia: https://doi.org/10.1182/bloodadvances.2025016966
OncoPharm
A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?
